Skip to main content
Premium Trial:

Request an Annual Quote

BHB Licenses Life Technologies' PCR Patents

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bar Harbor Biotechnology said today that it has licensed PCR and real-time PCR patents from Life Technologies.

The agreement enables BHB to provide contract research services based on its StellARray and XenoQ systems. Researchers can purchase assays based on those two technologies through BHB's exclusive distributor, Lonza. BHB would then perform the PCR services and analyze the data using the Global Patter Recognition analysis software, which is exclusive to the firm.

"We believe there are many laboratories that do not have the resources to utilize our technology," BHB's VP of Product Development, Dan Shaffer, said in a statement. "We wanted to change that and make it easier for all labs to make use of our systems."

BHB said that it has expanded its staff to incorporate the new services, and CEO Robert Phelps said that the expansion was made possible with support from the State of Maine. "This new expansion was part of a strategic plan to create new high tech jobs here in Maine," he said.

Financial terms of the agreement were not released.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.